At the meeting held on 14 July 2021, Assembly members agreed that the existing requirement for an individual to have been a Member of the Society for at least 12 years before being eligible for Fellowship should be removed. The following amendment to the Society’s Regulations will therefore take effect from 1 October 2021:
Regulation 2.1 – Categories of membership will be amended as follows:
(b) Fellows – may use the designatory letters FRPharmS after their name
To be eligible for Fellowship of the Society an individual must be a Member of the Society with not less than 12 years’ standing and must then be adjudged by the Panel of Fellows as having made an outstanding original contribution to the advancement of pharmaceutical knowledge or attained distinction in the science, practice, profession or history of pharmacy.
Postnominals
At the same meeting, Assembly members agreed that individuals who have successfully been credentialled by the Society would be permitted to add a descriptor to their RPS postnominals. The following amendment to the Society’s Regulations will therefore take effect from 1 October 2021 (addition in italics):
- Regulation 2.1 – Categories of membership will be amended as follows (addition in italics):
The Society shall have the following categories of membership and any other such categories as are established by Special Resolution of the Society. The requirements for admission to, or transfer to membership of any category shall, subject to the provisions of the Charter and these Regulations, be determined by the Assembly and shall be administered on their behalf by the Membership Committee.
Within all the following categories of membership the designated postnominal letters may be followed by such additional designated ‘descriptor’ postnominals as the Society may, from time to time, authorise. Details of such ‘descriptor’ postnominals shall be listed in Appendix J of these Regulations.
Any member who wishes to comment to the Assembly on the changes is asked to do so by 17 September 2021. Comments should be sent to president@rpharms.com.
